Docetaxel (DT) in anthracycline-pretreated advanced breast cancer (ABC): Toxicity and activity

被引：0
|
作者：
Ferraresi, V [1 ]
Vaccaro, A [1 ]
Milella, M [1 ]
D'Ottavio, AM [1 ]
Papaldo, P [1 ]
Nistico, C [1 ]
Thorel, MF [1 ]
Marsella, A [1 ]
Terzoli, E [1 ]
Cognetti, F [1 ]
机构：
[1] Regina Elena Canc Inst, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
88P
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [31] Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients
    Romeo Bascioni
    Francesca Giorgi
    Rosa Rita Silva
    Luigi Acito
    Lucio Giustini
    Giorgio De Signoribus
    Luciano Giuliodori
    Enrica Testa
    Breast Cancer Research and Treatment, 1997, 45 : 205 - 210
  • [32] Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients
    Bascioni, R
    Giorgi, F
    Silva, RR
    Acito, L
    Giustini, L
    DeSignoribus, G
    Giuliodori, L
    Testa, E
    BREAST CANCER RESEARCH AND TREATMENT, 1997, 45 (03) : 205 - 210
  • [33] A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer
    von Minckwitz, G
    Jonat, W
    Fasching, P
    du Bois, A
    Kleeberg, U
    Lück, HJ
    Kettner, E
    Hilfrich, J
    Eiermann, W
    Torode, J
    Schneeweiss, A
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 89 (02) : 165 - 172
  • [34] Docetaxel (D) and Gemcitabine (G) in anthracycline-resistant advanced breast cancer (AR-ABC)
    Fountzilas, G
    Bafaloukos, D
    Nikolaides, C
    Aravantinos, G
    Stathopoulos, G
    Apostolidou, K
    Kalofonos, H
    Kosmidis, P
    Pavlidis, N
    ANNALS OF ONCOLOGY, 1998, 9 : 26 - 26
  • [35] Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients
    Zelek, L
    Cottu, P
    Tubiana-Hulin, M
    Vannetzel, JM
    Chollet, P
    Misset, JL
    Chouaki, N
    Marty, M
    Gamelin, E
    Culine, S
    Dieras, V
    Mackenzie, S
    Spielmann, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) : 2551 - 2558
  • [36] A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer
    Gunter von Minckwitz
    Walter Jonat
    Peter Fasching
    Andreas du Bois
    Ulrich Kleeberg
    Hans-Joachim Lück
    Erika Kettner
    Jörn Hilfrich
    Wolfgang Eiermann
    Julie Torode
    Andreas Schneeweiss
    Breast Cancer Research and Treatment, 2005, 89 : 165 - 172
  • [37] Quality of life effects of Taxotere therapy in 184 patients with anthracycline-pretreated metastatic breast cancer
    Miles, DW
    Twelves, CJ
    Eggleton, SPH
    Burrell, A
    Hall, A
    ANNALS OF ONCOLOGY, 1998, 9 : 11 - 12
  • [38] A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer
    Li, Shufen
    Meng, Wenjing
    Zhang, Jibo
    Xie, Xiaojuan
    Hao, Chunfang
    Jia, Yongsheng
    Tong, Zhongsheng
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 (05) : 1069 - 1076
  • [39] Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer
    Kosmas, C
    Tsavaris, N
    Malamos, N
    Stavroyianni, N
    Gregoriou, A
    Rokana, S
    Polyzos, A
    BRITISH JOURNAL OF CANCER, 2003, 88 (08) : 1168 - 1174
  • [40] Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance
    Yong Wha Moon
    Joo Hyuk Sohn
    Hye Jin Choi
    Hyun Chang
    Byeong-Woo Park
    Seung Il Kim
    Seho Park
    Ja Seung Koo
    Yong Tai Kim
    Jae Kyung Roh
    Hyun Cheol Chung
    Joo-Hang Kim
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 425 - 431
12345